Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADIPOSTEM: Autologous ADRC in ALS
NCT03296501Phase 1Unknown
- Sponsor
- Mossakowski Medical Research Institute
- Start
- Oct 2015
- Primary completion
- Oct 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous adipose-derived stem/stromal cells in amyotrophic lateral sclerosis (ALS), sponsored by Mossakowski Medical Research Institute. Primary endpoint: Functional progression rate at 3 months. Status: unknown.
02
Drugs
autologous adipose-derived stem/stromal cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03296501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03296501.